{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T02:46:42Z","timestamp":1785293202019,"version":"3.55.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.cpcardiol.2024.102684","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T18:41:19Z","timestamp":1717008079000},"page":"102684","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The national financial burden of guideline directed medical therapy for heart failure patients from 2013 to 2021"],"prefix":"10.1016","volume":"49","author":[{"given":"Jude","family":"ElSaygh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shudhanshu","family":"Alishetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumudha","family":"Ramasubbu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2024.102684_bib0001","unstructured":"Centers for Medicare & Medicaid Services Data. Available at: https:\/\/data.cms.gov\/provider-summary-by-type-of-service\/medicare-part-d-prescribers\/medicare-part-d-prescribers-by-geography-and-drug\/data (Accessed: 02 November 2023)."},{"issue":"10","key":"10.1016\/j.cpcardiol.2024.102684_bib0002","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.cardfail.2023.07.006","article-title":"Heart failure epidemiology and outcomes statistics: a report of the heart failure society of America","volume":"29","author":"Bozkurt","year":"2023","journal-title":"J Card Fail"},{"issue":"16","key":"10.1016\/j.cpcardiol.2024.102684_bib0003","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1517\/14656566.2014.966078","article-title":"Empagliflozin for the treatment of type 2 diabetes","volume":"15","author":"Vidhya","year":"2014","journal-title":"Expert Opin Pharmacother"},{"issue":"15","key":"10.1016\/j.cpcardiol.2024.102684_bib0004","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with Empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2024.102684_bib0005","unstructured":"Jardiance (Empagliflozin) FDA approval history. Drugs.com. Available at: https:\/\/www.drugs.com\/history\/jardiance.html (Accessed: 31 October 2023)."},{"key":"10.1016\/j.cpcardiol.2024.102684_bib0006","unstructured":"Patient.boehringer. Available at: https:\/\/patient.boehringer-ingelheim.com\/us\/products\/jardiance\/heart-failure\/pricing#:\u223c:text=Each%20plan%20is%20different%20and,average%20of%20%24232%20per%20month.&text=With%20the%20JARDIANCE%20Savings%20Card,little%20as%20%2410%20per%20month. (Accessed: 31 October 2023)."},{"key":"10.1016\/j.cpcardiol.2024.102684_bib0007","unstructured":"Entresto (sacubitril and Valsartan) FDA approval history. Drugs.com. Available at: https:\/\/www.drugs.com\/history\/entresto.html (Accessed: 31 October 2023)."},{"issue":"11","key":"10.1016\/j.cpcardiol.2024.102684_bib0008","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013NEPRILYSIN inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2024.102684_bib0009","unstructured":"How much does Entresto cost per month? Drugs.com. Available at: https:\/\/www.drugs.com\/medical-answers\/entresto-cost-month-3544065\/(Accessed: 31 October 2023)."},{"issue":"10","key":"10.1016\/j.cpcardiol.2024.102684_bib0010","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2024.102684_bib0011","unstructured":"Finegold, K., 2021. Trends in the US uninsured population, 2010\u20132020. Department of Health & Human Services, Assistant Secretary for Planning and Evaluation, Office of Health Policy."}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280624003220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280624003220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T02:26:23Z","timestamp":1718418383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280624003220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":11,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0146280624003220"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102684","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The national financial burden of guideline directed medical therapy for heart failure patients from 2013 to 2021","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102684","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102684"}}